Piskulić Danijela, Olver James S, Maruff Paul, Norman Trevor R
Department of Psychiatry, University of Melbourne, Australia.
Hum Psychopharmacol. 2009 Aug;24(6):437-46. doi: 10.1002/hup.1046.
To assess effects of a semi-acute administration of buspirone in comparison to a placebo on cognitive function and negative symptoms in patients with schizophrenia and schizoaffective disorder.
In a 6-week, double-blind, placebo-controlled, independent groups study 18 subjects (14 males, four females) received in random order either placebo or buspirone (15-30 mg/day). A neuropsychological assessment using the Hopkins verbal learning test (HVLT) simple reaction time (SRT), choice reaction time (CRT), n-back spatial working memory task and the stroop colour and word test was performed at baseline and final visit. Symptom rating scales were administered at testing weeks 0, 2, 4 and 6.
Repeated measures ANOVA was used to examine changes in performance on tests over time. There were no statistically significant differences between placebo and buspirone treatments on either cognitive function measures or symptom ratings.
Semi-acute adjunct treatment with buspirone may be too short to be clinically efficacious in patients with schizophrenia. Intrinsic activation of 5-HT(1A) receptors by atypical antipsychotics may hinder the ability of buspirone to further improve cognitive functions. Buspirone did not affect clinical outcomes for this chronically ill group of patients being treated with atypical antipsychotic drugs.
评估与安慰剂相比，半急性给予丁螺环酮对精神分裂症和分裂情感性障碍患者认知功能及阴性症状的影响。
在一项为期6周的双盲、安慰剂对照、独立组研究中，18名受试者（14名男性，4名女性）随机接受安慰剂或丁螺环酮（15 - 30毫克/天）治疗。在基线和末次访视时，使用霍普金斯言语学习测验（HVLT）、简单反应时间（SRT）、选择反应时间（CRT）、n - 回溯空间工作记忆任务以及斯特鲁普颜色和文字测验进行神经心理学评估。在第0、2、4和6周测试时使用症状评定量表。
采用重复测量方差分析来检验随时间推移测试表现的变化。在认知功能测量或症状评定方面，安慰剂和丁螺环酮治疗之间没有统计学上的显著差异。
丁螺环酮的半急性辅助治疗可能时间过短，对精神分裂症患者临床无效。非典型抗精神病药物对5 - HT(1A)受体的内在激活可能会阻碍丁螺环酮进一步改善认知功能的能力。丁螺环酮对正在接受非典型抗精神病药物治疗的这组慢性病患者的临床结局没有影响。
